About Michael T. Ledet, M.D.

LICENSURES/CERTIFICATIONS

• 1987 – Present, Alabama Medical Licensure Commission (12669)
• 1998 – 2013, 2019 Member, America’s Best Doctors
• 2020, Leading Physicians of the World

BOARD CERTIFICATIONS

• Current Family Medicine
• Current Sleep Medicine
• Current Lipidology

PUBLICATIONS

Ledet, M., Sleeping Away Diabetic Complications, Practical Diabetology; Sept/Oct 2010

SOCIETIES

• American Academy of Sleep Disorders
• National Lipid Association
• American Society for Preventive Cardiology (ASPC)

AFFILIATIONS

2014 – Present Coastal Clinical Research, Inc.
PI/Sub-I

SPEAKER’S BUREAU AFFILIATIONS

• Amarin Pharmaceuticals
• Amgen Pharmaceuticals
• Eisai Pharmaceuticals
• Esperion Pharmaceuticals
• Galt Pharmaceuticals
• Harmony Biosciences
• Idorsia Pharmaceuticals
• Jazz Pharmaceuticals
• Regeneron Pharmaceutical

MEDICAL ADVISOR

Galt Pharmaceuticals

RESEARCH

1999 Sub-Investigator; Amgen, Inc.; Long-Term Safety of Daily Subcutaneous Injections of Anakinra in Patients with Rheumatoid Arthritis

2000 Investigator; Glaxo Wellcome; Primary Care Study to Estimate the Prevalence of Sexual Dysfunction Reported by Patients Currently Taking New Generation Antidepressant Medication for a Diagnosis of Depression

2000 Sub-Investigator; Amgen Inc.; Placebo Controlled Trial to Study the Ability of IL-1ra to Retard Joint Destruction, and Evaluate the Long Term Safety of IL-1ra, in Subjects with Rheumatoid Arthritis

2000 Investigator; Bristol-Myers Squibb; Pravastatin Inflammation / CRP Evaluation Trial

2000 Investigator; Glaxo Wellcome; Patient Treatment for and Satisfaction with Migraine Therapy: Imitrex Tablets versus Current Therapy

2000 Investigator; Bristol-Myers Squibb; Omapatrilat Cardiovascular Treatment versus Enalapril (OCTAVE)

2001 Investigator; Glaxo Wellcome; Surviellance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus Salmeterol Twice Daily

2001 Investigator; Ortho-McNeil; Safety and Efficacy Study of Levofloxacin 750mg Once Daily for Five Days vs. Levofloxacin 500mg Once Daily for Ten Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults

2001 Investigator; Ortho-McNeil; Open Label Study to Evaluate the Safety and Efficacy of Levofloxacin 750mg Once Daily for Five Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults

2001 Investigator; Ortho-McNeil; A Randomized, Multicenter, Blinded Study of the Efficacy and Safety of High-Dose (750MG), Short-Course (3-5 Days) Levofloxacin Therapy in Uncomplicated and Complicated Acute Bacterial Exacerbation of Chronic Bronchitis

2001 Investigator; Aventis Pharmaceuticals; Telithromycin Respiratory Effectiveness Assessment Trial (TREAT)

2002 Investigator; GlaxoSmithKline; Open Label Study Assessing Paxil CR in Subjects with Major Depressive Disorder who Discontinued Treatment with SSRS or a SSNRI due to Intolerability

2003 Investigator; Neurocrine Biosciences, Inc.; Phase III Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of NBI-34060 in Adult Patients with Primary Insomnia

2004 Investigator; Sepracor, Inc.; The Efficacy of Eszopiclone 3mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause

2004 Investigator; NeurogesX, Inc.; Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction with NGX-4010 for the Treatment of Neuropathic Pain

2004 Investigator; Pfizer, Inc.; Randomized, Double-Blind, Placebo-Controlled, Multicenter Actual Use Study of the Safety and Tolerability of Gabapentin 500mg in a Potential OTC Population

2005 Investigator; Neurocrine Biosciences, Inc.; Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a modified Release Formulation of NBI-34060 in Primary Insomnia Patients with Sleep Maintenance Difficulties

2006 Eli Lilly & Co.; A Comparison of CS-747 and Clopidrogel in Acute Coronary Syndrome Subjects who are to undergo Percutaneous Coronary Intervention/TIMI-38

2007 Investigator: Sanofi-Aventis; A gLycemic control Evaluation of Glimerpiride versus Rimonabant on tOp of metformin in type 2 diabetes/ALLEGRO study.

2012 Sub-Investigator; The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)

2012 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY COMBO 1)

2015 Alder Biopharmaceuticals ALD403-CLIN-005 A Parallel Group, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients with Chronic Migraine

2015 Daiichi Sankyo DS5565-A-E311A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia

2015 Daiichi Sankyo DS5565-A-E312 An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia

1VIT14037: A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)

1002-048: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg/day as Add-on to Ezetimibe Therapy in Patients with Elevated LDL-C

Protocol: JZP080-301 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26, ZEBOV and MVA-BN-Filo in Adult Participants